Stem Cell Therapy in Mental Retardation

NCT02245724 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-10-25

No results posted yet for this study

Summary

The purpose of this study was to analyze the benefit of autologous mononuclear cell therapy in mental retardation.

Conditions

  • Mental Retardation

Interventions

BIOLOGICAL

Stem Cell

Autologous bone marrow mononuclear cell transplantation

Sponsors & Collaborators

  • Neurogen Brain and Spine Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2016-03-31
Completion
2016-09-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02245724 on ClinicalTrials.gov